Gemcitabine in the treatment of ovarian cancer

被引:19
作者
Hansen, SW [1 ]
Tuxen, MK
Sessa, C
机构
[1] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Osped San Giovanni, Dept Oncol, Bellinzona, Switzerland
关键词
carboplatin; combination chemotherapy; ovarian cancer; gemcitabine; paclitaxel;
D O I
10.1023/A:1008359418422
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gemcitabine is a new nucleoside antimetabolite with established activity against solid tumours. In previously treated patients the response rate with the drug alone was around 13%. Combination therapy with gemcitabine-cisplatin or gemcitabine-paclitaxel induced responses in 53 and 40% respectively. In previously untreated patients with poor prognostic features a 24% response rate was reported for the drug alone, but in combination with cisplatin remissions were found in 53%-71% of patients. Gemcitabine, paclitaxel, and carboplatin (or cisplatin) in combination appeared to be a feasible and active combination. In a pilot with eight previously treated patients all obtained a remission and in untreated patients a remission occurred in all evaluable patients either clinically or measured by a decrease of CA 125. Dose-limiting toxicity is mainly haematological.
引用
收藏
页码:51 / 53
页数:3
相关论文
共 14 条
[1]  
BAUKNECHT T, 1998, P AM SOC CLIN ONCOL, V17, P1376
[2]  
Bergman AM, 1996, CLIN CANCER RES, V2, P521
[3]  
HUANG P, 1991, CANCER RES, V51, P6110
[4]  
KRAKOWSKI I, 1998, P AN M AM SOC CLIN, V17, P1373
[5]  
KUNKEL LM, 1998, P AN M AM SOC CLIN, V17, P1379
[6]   PHASE-II STUDY OF GEMCITABINE (2',2'-DIFLUORODEOXYCYTIDINE) IN PREVIOUSLY TREATED OVARIAN-CANCER PATIENTS [J].
LUND, B ;
HANSEN, OP ;
THEILADE, K ;
HANSEN, M ;
NEIJT, JP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20) :1530-1533
[7]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[8]  
NOGUE M, 1998, P AM SOC CLIN ONCOL, V17, P1377
[9]  
Plunkett W, 1996, SEMIN ONCOL, V23, P3
[10]  
POOLE CJ, 1998, P AN M AM SOC CLIN, V17, P1380